MiMedx amniotic allografts

Register to receive a free U.S. Soft Tissue Reinforcement and Regeneration Market report synopsis and brochure

MiMedx Group, Inc. announced recently that in light of the media attention and in the wake of concerns related to the Zika virus, the Company is reiterating its long standing processing safety standards for the terminal sterilization of MiMedx amniotic allografts. The MiMedx flagship amniotic allografts have always been terminally sterilized, and the Company’s proprietary PURION® Process has continually used terminal sterilization as an essential part of the process. In anticipation of questions related to the Zika virus, MiMedx is reconfirming the rigorous product safety methods and practices followed by the Company in the processing of its amniotic allografts as well as restating its precise standards for screening of placenta donors.

Bill Taylor, President and COO, commented, “With the emergence and propagation of the Zika virus, we anticipated that questions would soon arise, and we decided that, in advance of any questions, we would reconfirm our established safety processes to reassure patients and physicians of the exacting terminal sterilization methodology and the standards we employ to assure the sterility of our amniotic allografts for potential microbiological and viral transmissions. With the heightened concerns related to the Zika virus, we expect that the detailed steps taken by all other tissue processors of placenta-based products will be reviewed to ensure their product safety and the processes utilized do adequately reduce the potential for microbiological and viral transmissions. MiMedx has continuously made assessments and implemented modifications to our original processes in both the donor screening and the processing functions of our business to maximize product safety. We have recently introduced our new lyophilized version of OrthoFlo which is also terminally sterilized to the same standards as our other amniotic allografts.”

It should be noted that aseptic processes, which many tissue products utilize, are usually validated to claim a less than 1 in 1,000 probability of a non-sterile unit per FDA Guidance and ISO standards. The probability of an occurrence of a non-sterile unit in products produced by MiMedx is significantly lower, however. Specifically, MiMedx’s process and terminal sterilization validations provide a less than 1 in 1 million probability of a non-sterile unit, which is at least a 1,000 times higher safety margin than typical aseptically processed tissue products.

The FDA and the American Association of Tissue Banks (“AATB”) have issued guidance on donor eligibility and screening recommendations to reduce the risk of transmission of Zika virus via human tissues. MiMedx has been processing its amniotic allografts based on those recommendations since they were published.

For Further Information
More on the soft tissue reinforcement and regeneration device market in the U.S. can be found in a report suite published by iData Research entitled U.S. Market for Soft Tissue Reinforcement and Regeneration. The suite covers reports on the following markets: Breast Reconstruction, Dural Repair, Skin Repair, Dental Soft Tissue Regeneration, Hernia Repair, Vaginal Sling, and Sports Medicine and Tendon Reinforcement.

The iData report series on soft tissue reinforcement and regeneration devices covers the United States, Germany, France, the United Kingdom, Italy, Spain, Belgium, Netherlands, Luxembourg, Denmark, Finland, Norway, Sweden, Austria, Switzerland and Portugal. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about global soft tissue reinforcement and regeneration market data or procedure data, register online or email us at [email protected] for a U.S. Market for Soft Tissue Reinforcement and Regeneration brochure and synopsis.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.

About iData Research
iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.


Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook: facebook.com/iDataResearch
Follow us on LinkedIn: linkedin.com/company/idata-research
Follow us on Twitter: twitter.com/iDataResearch